![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsored by: |
GlaxoSmithKline |
---|---|
Information provided by: | GlaxoSmithKline |
ClinicalTrials.gov Identifier: | NCT00697125 |
The purpose of this study is to evaluate the immunogenicity and reactogenicity of various formulations of recombinant hepatitis B vaccine with different adjuvants in healthy adult volunteers following the 0, 1, 6 months schedule
Condition | Intervention | Phase |
---|---|---|
Hepatitis B |
Biological: Engerix™-B Biological: HBV-MPL vaccine (208129) Biological: Hepatitis B vaccine, experimental formulation |
Phase II |
Study Type: | Interventional |
Study Design: | Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator), Parallel Assignment, Safety/Efficacy Study |
Official Title: | Study to Evaluate the Immunogenicity and Reactogenicity of Various Formulations of GSK Biologicals' (Previously SmithKline Beecham Biologicals') Recombinant Hepatitis B Vaccine With Different Adjuvants in Healthy Adult Volunteers |
Enrollment: | 60 |
Study Start Date: | June 1993 |
Study Completion Date: | July 1994 |
Primary Completion Date: | July 1994 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Group A: Active Comparator |
Biological: Engerix™-B
Intramuscular injection, 3 doses
|
Group B: Experimental |
Biological: Hepatitis B vaccine, experimental formulation
Intramuscular injection, 3 doses
|
Group C: Experimental | Biological: HBV-MPL vaccine (208129) |
At the time of conduct of this study, the sponsor GlaxoSmithKline was known by its former name SmithKline Beecham
Ages Eligible for Study: | 18 Years to 40 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Responsible Party: | GSK ( Isabelle Harpigny ) |
Study ID Numbers: | 208129/005 |
Study First Received: | June 11, 2008 |
Last Updated: | June 11, 2008 |
ClinicalTrials.gov Identifier: | NCT00697125 |
Health Authority: | Belgium: Ministry of Social Affairs, Public Health and the Environment |
Hepatitis B Engerix™-B Recombinant hepatitis B vaccine |
Virus Diseases Hepatitis Liver Diseases Digestive System Diseases |
Hepatitis B Hepatitis, Viral, Human DNA Virus Infections Healthy |
Hepadnaviridae Infections |